Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects

Bibliography

• ACQUADRO M, BORODIC GE: Treatment of myofascial pain with botulinum toxin. Anesthesiology (1994) 80(3)705–706.
   Google Scholar
• BORODIC GE, MILLS L, JOSEPH M: Botulinum A toxin for adult onset spasmodic torticollis. Plastic and Reconstructive Surgery (1991) 87(2):285–289.
   PubMed Web of Science ®Google Scholar
• JOHNSON EA: Neurotoxigenic clostridia. In: Cram-Positive Pathogens. Fischetti Vet al. (Ed.), American Society for Microbiology, Washington, DC, USA (2000):540–549.
   Google Scholar
• SUGIYAMA H: Clostridium botulinum neurotoxin. Microbial. Rev 44:419–448.
   Google Scholar
• OGUMA K, FUJINAGA Y, INOUE K, YOKOTA K, WATANABE T, OHYAMA et al.: Structure and function of Clostridium botulinum progenitor toxin. In: 11/licrobial Foodborne Diseases: Mechanisms of Pathogenesis and Toxin Synthesis. Cary JW, Linz JE, Bhatnagar D (Eds.), Technomic Publishing, Co., Inc.
   Google Scholar
• SCHANTZ EJ, JOHNSON EJ: Botulinum toxin: the story of its development for the treatment of human disease. Perspect. Biol. Med. (1997) 40:317–327.
   PubMed Web of Science ®Google Scholar
• JOHNSON EA: Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu. Rev Microbial. (1999) 53:551–575.
   PubMed Web of Science ®Google Scholar
• SCHIAVO G, MATTEOLI M, MONTECUCCO C: Neurotoxins affecting neuroexocytosis. Physial Rev (2000) 80:717–766.
   PubMed Web of Science ®Google Scholar
• ROSETTO 0, SEVESO, M, CACCIN E SCHIAVO G, MONTECUCCO C: Tetanus and botulinum neurotoxins: turning bad guys into good by research. Textron (2001) 39:27–41.
   Google Scholar
• MCNEW JA, PARLATI E FUKUDA R, JOHNSTON RJ, PAZ K, PAUMET F et al: Compartmental specificity of cellular membrane fusion encoded in SNARE proteins. Nature (2000) 407:153–159.
   PubMed Web of Science ®Google Scholar
• LIN RC, SCHELLER RH: Mechanisms of synaptic vesicle exocytosis. Ann. Rev. Cell Dev. Biol. (2000) 16:19–49.
   PubMed Web of Science ®Google Scholar
• CHEN YA, SCALES SJ, PATEL SM, DOUNG YC, SCHELLER RH: SNARE complex formation is triggered by Ca2+ and drives membrane fusion. Cell (1999) 97:165–174.
   PubMed Web of Science ®Google Scholar
• SCHANTZ EJ, JOHNSON EA: Propertiesand use of botulinum toxin and other microbial neurotoxins in medicine. Microbial Rev (1992) 56:80–99.
   PubMedGoogle Scholar
• JOHNSON EA, GOODNOUGH MC: Preparation and properties of botulinum toxin type A for medical use. In: Handbook of Dystorria. Tsui JKC, Caine DB (Eds.), Marcel-Dekker, Inc., New York, USA (1995):347–365.
   Google Scholar
• BORODIC G, JOHNSON E, GOODNOUGH M, SCHANTZ E: Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology (1996) 46:26–29.
   PubMed Web of Science ®Google Scholar
• BORODIC GE, JOSEPH M, FAY L, COZZOLINO D, FERRANTE R: Botulinum A toxin for the treatment of spasmodic torticollis, dysphagia and Regional Toxin Spread. Head & Neck (1990) 12:392–398.
   PubMed Web of Science ®Google Scholar
• BORODIC GE, ALDERSEN K, PEARCE LB, FERRANTE R: Histologic changes in muscle and clinciopathologic correlations after therapeutic botulinum toxin administration. In: Botulinum Toxin Therapy Jankovic J, Hallett M (Eds.), Marcel Dekker, Inc., New York and Hong Kong (1994):119–158.
   Google Scholar
• BORODIC GE, FERRANTE R, PEARCE LB, SMITH K: Histologic assessment of dose related diffusion and muscle fiber response after therapeutic botulinum toxin 1541 Expert Op/n. lnvestig. Drugs (2001) 10(8) injections. Movement Disord. (1994) 9(1):31–39.
   Google Scholar
• BORODIC GE, PEARCE LB, SMITH K, JOSEPH M: Botulinum toxin for spasmodic torticollis, multiple vs. single point injections per muscle. Head & Neck (1992) 14:33–37.
   PubMed Web of Science ®Google Scholar
• DUCHEN LW: Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles. _J. Neurof Neuroswg. Psych. (1970) 33(1):40–54.
   PubMed Web of Science ®Google Scholar
• BORODIC GE, SMITH K, PEARCE LB, FERRANTE R: Botulinum B toxin as an alternative to botulinum A Toxin, a histologic study. OphthaL Plastic Reconstruc. Surg. (1993) 9(3):182–190
   PubMed Web of Science ®Google Scholar
• HARRIS CP, ALDERSON K, NEBEKER J, HOLDS JB, ANDERSON RL: Histologic features of human orbicularis oculi treated with botulinum A toxin. Arch. Ophthalmal (1991) 109(3):393–395.
   PubMed Web of Science ®Google Scholar
• PEARCE LB, BORODIC GE, FIRST E, MACCALLUM R: Measurement of botulinum toxin activity:evaluation of the lethality assay. TaxicaL AppL Pharmacol. (1994) 128:69–77.
   PubMed Web of Science ®Google Scholar
• PEARCE LB, BORODIC GE, JOHNSON EA, FIRST ER, MACCALLUM R: The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. Toxicon (1997) 33:217–227.
   Web of Science ®Google Scholar
• KUPFER C: Selective block on synaptic transmission in ciliary ganglion by type A botulinum toxin in rabbits. Proc. Soc. Exp. Biol. Med. (1958) 99474–99476.
   Google Scholar
• LEVY Y, KREMER I, SHAVIT S, KORCZYN AD: The pupillary effects of retrobulbar injection of botulinum toxin A (oculinum) in albino rats. Invest. Ophthalmal. Vis. Sci (1991) 32(1):122–125.
   PubMed Web of Science ®Google Scholar
• BOROOJERDI B, FERBERT A, SCHWARZ M, HERATH H, NOTH J: Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. Neural. Neurosurg. Psych. (1998) 65(1):111–114
   PubMed Web of Science ®Google Scholar
• SHAARI CM, WU BL, BILLER HE CHUANG SK, SANDERS I: Botulinum toxin decreases salivation from canine submandibular glands. OtalaryngaL Head Neck Surg. (1998) 118(4):452–457
   PubMed Web of Science ®Google Scholar
• SOLOMON BA, HAYMAN R: Botulinum toxin type A therapy for palmar and digital hyperhidrosis. j Am. Acad. Dermatal (2000) 42(6):1026–1029.
   PubMed Web of Science ®Google Scholar
• KELLOGG DL JR, PERGOLA PE, PIEST KL, KOSIBA WA, CRANDALL CG, GROSSMANN M, JOHNSON JM: Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission. Circ. Res. (1995) 77(6):1222–1228.
   PubMed Web of Science ®Google Scholar
• JOHNSON EA, GOODNOUGH MC: Botulism. In: Tapley and Wilson's Microbiology and Microbial Infections. Vol. 3, Bacterial Infections. Collier L, Balows A, Sussman M (Eds.), Arnold, London, UK (1998):723–741.
   Google Scholar
• KELLER JE, NEALE EA, OYLER G, ADLER M: Persistence of botulinum neurotoxin action in spinal cord cells. FELS Lett. (1999) 456:137–142.
   PubMed Web of Science ®Google Scholar
• DE PAIVA A, MEUNIER FA, MOLGO J, AOKI KR, DOLLY JO: Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl. Acad. Sci. USA (1999) 96:3200–3205.
   PubMed Web of Science ®Google Scholar
• ADLER M, KELLER JE, SHERIDAN RE, DESHPANDE SS: Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon (2001) 39:233–243.
   PubMed Web of Science ®Google Scholar
• SMITH LDS, SUGIYAMA H: Botulism. The Organism, Its Toxins, the Disease, (2nd Edition) Charles C Thomas, Springfield, IL, USA.
   Google Scholar
• WHITLOCK RH: Interagency botulinummeeting. Natick, Massachusetts; USA. (1991).
   Google Scholar
• LEW ME ADORNATO BT, DUANE DD, DYKSTRA DD, FACTOR SA, MASSEY JM etal.: Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology (1997) 49(3):701–707.
   PubMed Web of Science ®Google Scholar
• CULLIS PA, O'BRIEN CE TRUONG DD, KOLLER M, VILLEGAS TP, WALLACE: JD: Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients. Adv. Neural. (1998) 78:227–230.
   PubMedGoogle Scholar
• GREENE P, FAHN S, DIAMOND B: Development of resistance to botulinum toxin type A in patients with torticollis. Mov. Disord (1994) 2:213–217.
   Google Scholar
• GREENE PE, FAHN S: Use of botulinumtoxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov. Disord. (1993) 4:479–483.
   Google Scholar
• DAUER WT, BURKE RE, GREENE P, FAHN S: Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain (1998) 121:547–560.
   PubMed Web of Science ®Google Scholar
• TRAVEL JG, SIMONS DG: Myofascial pain and dysfunction. William and Wilkins, Baltimore, USA (1983):29,32.
   Google Scholar
• PORTA MA: Comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain (2000) 85(1-2):101–105
   PubMed Web of Science ®Google Scholar
• WHEELER AH, GOOLKASIAN P, GRETZ SS: A randomized, double-blind,prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine (1998) 23(15):1662–1666.
   PubMed Web of Science ®Google Scholar
• CHESHIRE WP, ABASHIAN SW, MANN JD: Botulinum toxin in thetreatment of myofascial pain syndrome. Pain (1994) 59(1):65–69.
   PubMed Web of Science ®Google Scholar
• FREUND B, SCHWARTZ M, SYMINGTON JM: Botulinum toxin: new treatment for temporomandibular disorders. Br j Oral Maxillofac. Surg. (2000) 38(5):466–471.
   PubMed Web of Science ®Google Scholar
• WALSH, FB, HOYT, WF: Textbook of Clinical Neuro-Ophthalmology 3rd Ed. Williams and Wilkins (1969), Baltimore, USA.
   Google Scholar
• BORODIC GE: Photophobia, an unrecognized component of essential blepharospasm and Meige Syndrome. American Soden, of Ophthalmic Plastic and Reconstructive Surgery Chicago, Illinois, USA (1996).
   Google Scholar
• FEIWELL RJ, BLACK KJ, MCGEE-MINNICH LA, SNYDER AZ, MACLEAD AM, PERLMUTTER JS: Diminished regional cerebral blood flow response to vibration in patients with blepharospasm. Neurology (1999) 52(2):291–297.
   PubMed Web of Science ®Google Scholar
• BOCK, JB, SCHELLER, RH: SNARE proteins mediate lipid bilayer fusion. Proc. NatL Arad Sci. USA (1999) 96:12227–12229.
   PubMed Web of Science ®Google Scholar
• ELEOPRA R, MONTECUCCO C: On the action of botulinum neurotoxins A and E at cholinergic terminals. j Physial. Paris (1998) 92(2):135–139.
   PubMed Web of Science ®Google Scholar
• SILBERSTEIN S, MATHEW N, SAPER J, JENKINS S: Botulinum toxin type A as a migraine preventive treatment. From the BOTOX Migraine Clinical Research Group. Headache (2000) 40(6):445–450.
   Google Scholar
• HEADACHE CLASSIFICATION COMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia (1988) 8:(Suppl 7):1–96.
   Google Scholar
• BUZZI MG, MOLKOWITZ MA: The trigemino-vascular system and migraine. Patho. Biol. (Paris) (1992) 40(4):313–317.
   PubMed Web of Science ®Google Scholar
• BUZZI MG, DIMITEIADOU V, THEOHARIDES TC, MOSKOVITZ MA: 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the ratdura mater after trigeminal stimulation. Brain Res. (1992) 583(1-2):137–149.
   PubMed Web of Science ®Google Scholar
• BUZZI MG, BONAMINI M, MOSKOWITZ MA: Neurogenic model of migraine. Cephalalgia (1995) 15(4):277–280.
   PubMed Web of Science ®Google Scholar
• MOSKOWITZ MA, BUZZI MG: Neuroeffector functions of sensory fibres: implications for headache mechanisms and drug actions. j Neural. (1991) 238\(Suppl. 1):S18–22
   Google Scholar
• FERRARI MD, SAXENA PR: Clinical effects and mechanism of action of sumatriptan in migraine. Cilia. Neural Neurosurg. (1992) 94(Suppl.):573–577
   Google Scholar
• HEATLEY RV, DENBURG JA, BAYER N, BIENENSTOCK J: Increased plasma histamine levels in migraine patients. Chit. Allergy (1982) 12(2):145–149.
   Web of Science ®Google Scholar
• MENDELL LM, ALBERS KM, DAVIS BM: Neurotrophins, nociceptors, and pain. MiCTOSC. Res. Tech. (1999) 45(4-5):252–261.
   PubMed Web of Science ®Google Scholar
• LEWIN GR, MENDELL LM: Nerve growth factor and nociception. Trends Neurosci. (1993) 16(9):353–359.
   PubMed Web of Science ®Google Scholar
• DINES KC, POWELL HC: Mast cell interactions with the nervous system: relationship to mechanisms of disease. Neurapathol. Exp. Neural (1997) 56(6):627–640.
   PubMed Web of Science ®Google Scholar
• LEON A, BURIANI A, DAL TOSO R, FABRIS M, ROMANELLO S, ALOE L, LEVI-MONTALCINI R: Mast cells synthesize, store, and release nerve growth factor. Proc. Natl. Acad. Li. USA (1994) 91(9):3739–3743.
   PubMed Web of Science ®Google Scholar
• MEIJER F, RUIJTER JM, VAN DELFT JL, VAN HAERINGEN NJ: Nitric oxide induces vascular permeability changes in the guinea pig conjunctiva. Eur. j Pharmacy]. (1995) 284(1-2):61–67.
   PubMed Web of Science ®Google Scholar
• CHEN X, LEVINE JD: NOS inhibitor antagonism of PGE2-induced mechanical sensitization of cutaneous C-fiber nociceptors in the rat. Neurophysiology (1999) 81(3):963–966.
   PubMed Web of Science ®Google Scholar
• BAKER MK, SMUTS HM STASSEN JM ROSSOW E, BARNARD PW: Botulinum type A toxin as a prophylactic treatment of chronic tension type headache. Proceedings of the International Conference- Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Orlando, Florida (1999).
   Google Scholar
• BORODIC GE ACQUADRO M: Experience in utilization of botulinum toxin for the treatment of head and neck pain disorders. Proceedings of the International Conference- Basic and Therapeutic Aspects of &Minim and Tetanus Toxins. Orlando, Florida, USA (1999).
   Google Scholar
• SOTER NA, WASSERMAN SI, AUSTEN KF, MCFADDEN ER JR.: Release of mast-cell mediators and alterations in lung function in patients with cholinergic urticaria. N Engl. j Med. (1980) 302(11):604–608.
   Google Scholar
• SHEFFER AL, SOTER NA, MCFADDEN ER Jr, AUSTEN KF: Exercise-induced anaphylaxis: a distinct form of physical allergy. j Allergy OM. Immune]. (1983) 71(3):311–316.
   PubMed Web of Science ®Google Scholar
• IMAMURA T, KAMBARA T: Substance P as a potent stimulator of sneeze responses in experimental allergic rhinitis of guinea pigs. AgentrActions (1992) 37(3-4):245–249.
   Google Scholar
• KO SM, KIM MK, KIM JC: The role of nitric oxide in experimental allergic conjunctivitis. Cornea (2000) 19(1):84–91.
   PubMed Web of Science ®Google Scholar
• FUJISHIMA H, TAKEYAMA M, TAKEUCHI T, SAITO I, TSUBOTA K: Elevated levels of substance P in tears of patients with allergic conjunctivitis and vernal keratoconjunctivitis. CBI]. Exp. Allergy (1997) 27(4):372–378
   PubMed Web of Science ®Google Scholar
• YAMAJI M, TAKADA M, FUJIWARA R, OHISHI H, IZUSHI K, SUGIMOTO Y, KAMEI C: Role of substance P in experimental allergic conjunctivitis in guinea pigs. Meth. Find Exp. OM. Pharmacy]. (1997) 19(9):637–643.
   PubMed Web of Science ®Google Scholar
• FIGINI M, JAVDAN P, CIONCOLINI F, GEPPETTI P: Involvement of tachykinins in plasma extravasation induced by bradykinin and low pH medium in the guinea-pig conjunctiva. Br. I Pharmacy]. (1995) 115(1):128–132
   PubMed Web of Science ®Google Scholar
• PEDERSEN-BJERGAARD U, NIELSEN LB, JENSEN K, EDVINSSON L, JANSEN I, OLESEN J: Calcitonin gene-related peptide, neurokinin A and substance P: effects on nociception and neurogenic inflammation in human skin and temporal muscle. Peptides (1991) 12(2):333–337.
   PubMed Web of Science ®Google Scholar
• NORDAHL S, ALSTREGREN P, KOPP S: Tumor necrosis factor-alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain. I Oral Maxillafac. Surg. (2000) 58(5):525–530.
   PubMed Web of Science ®Google Scholar
• AWAD EA: Interstitial myofibrositis: hypothesis on mechanism. Arch. Phys. Med. (1973) 54:440–453.
   Google Scholar
• ANICHINI M, CESARETTI S, LEPORI M et al.: Substance P in the serum of patients with rheumatoid arthritis. Rev Rheum. Engl. Ed (1997) 64(1):18–21.
   PubMedGoogle Scholar
• GRONBLAD M, KONTTINEN YT, KORKALA 0, LIESI P, HUKKANEN M, POLAK JM: Neuropeptides in synovium of patients with rheumatoid arthritis and osteoarthritis. j Rheumatal. (1988) 15(12):1807–1810.
   PubMed Web of Science ®Google Scholar
• LEVINE JD, CLARK R, DEVOR M, HELMS C, MOSKOWITZ MA, BASBAUM Al: Intraneuronal substance P contributes to the severity of experimental arthritis. Science (1984) 226:547–549.
   PubMed Web of Science ®Google Scholar
• SMITH GD, HARMAR AJ, MCQUEEN DS, SECKL JR: Increase in substance P and CGRP, but not somatostatin content of innervating dorsal root ganglia in adjuvant monoarthritis in the rat. Neurosci. Lett. (1992) 137:257–260.
   PubMed Web of Science ®Google Scholar
• OSTLERE LS, COWEN T, RUSTIN MH: Neuropeptides in the skin of patients with atopic dermatitis. CBI]. Exp. Dermatal. (1995) 20(6):462–467.
   PubMed Web of Science ®Google Scholar
• TOGIAS A: Unique mechanistic features of allergic rhinitis. I Allergy Clin. Immune]. (2000) 105(6 Pt 2):5599–5604.
   Google Scholar
• DAEMAN M, KURVERS H, BULLENS P, BARENDSE G, VAN KLEEF M, VAN DEN WILDENBERG F: Neurogenic inflammation and reflex sympathetic dystrophy (in vivo and in vitro assessment in an experimental model). Acta Orthop. Belg. (1998) 64(4):441–447.
   PubMedGoogle Scholar
• JOOS GF, GERMONPRE PR, PAUWELS RA: Role of tachykinins in asthma. Allergy (2000) 55(4):321–337.
   PubMed Web of Science ®Google Scholar
• MERAYO-LLOVES J, CALONGE M, FOSTER CS: Experimental model of allergic conjunctivitis to ragweed in guinea pig. Cum: Eye. Res. (1995) 14(6):487–494
   PubMed Web of Science ®Google Scholar
• FIELDS HL: Treatment of trigeminal neuralgia. N Engl. j Med. (1996) 334 (17):1125–1126.
   PubMed Web of Science ®Google Scholar
• WILKINSON HA: Trigeminal nerve peripheral branch phenol/glycerol injections for tic douloureux. j Neurosurg. (1999) 90(5):828–832.
   PubMed Web of Science ®Google Scholar
• YOON KB, WILES JR, MILES JB, NURMIKKA TJ: Long term outcome of percutaneous thermocoagulation for trigeminal neuralgia. Anesthesia (1999) 54(8):803–808)
   PubMed Web of Science ®Google Scholar
• BARKER F, JENNETTA P, BISSONETTEP et al.: The long term outcome of microvascular decompression for trigeminal neuralgia. N Engl. J Med. (1996) 334:1077–1083.
   PubMed Web of Science ®Google Scholar
• WOOLF CJ, MANNION RJ: Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet (1999) 353:1959–1964.
   PubMed Web of Science ®Google Scholar
• WOOLF CJ, COSTIGAN M: Transcriptional and post-translational plasticity and the generation of inflammatory pain. Proc. Nati Acad. Li. USA (1999) 96:7723–7730.
   PubMed Web of Science ®Google Scholar